
Sign up to save your podcasts
Or


Ira Jersey, Chief US interest rate strategist for Bloomberg Intelligence, discusses how Treasuries might react to a government shutdown on Friday. Michael Shah, Pharma Analyst with Bloomberg Intelligence, joins to discuss Novo Nordisk, Ozempic, and the weight loss drug push. Jake Saper, Emergence Capital General Partner, joins to talk about investment strategies, tech, and markets. Jereme Sylvain, CFO at DexCom (NASDAQ: DXCM), joins to discuss company earnings, its initiatives in healthcare and specifically for diabetes, and outlook for the firm and industry. Hosted by Paul Sweeney and Matt Miller.
See omnystudio.com/listener for privacy information.
By Bloomberg3.8
381381 ratings
Ira Jersey, Chief US interest rate strategist for Bloomberg Intelligence, discusses how Treasuries might react to a government shutdown on Friday. Michael Shah, Pharma Analyst with Bloomberg Intelligence, joins to discuss Novo Nordisk, Ozempic, and the weight loss drug push. Jake Saper, Emergence Capital General Partner, joins to talk about investment strategies, tech, and markets. Jereme Sylvain, CFO at DexCom (NASDAQ: DXCM), joins to discuss company earnings, its initiatives in healthcare and specifically for diabetes, and outlook for the firm and industry. Hosted by Paul Sweeney and Matt Miller.
See omnystudio.com/listener for privacy information.

977 Listeners

1,173 Listeners

2,175 Listeners

427 Listeners

970 Listeners

196 Listeners

1,044 Listeners

191 Listeners

71 Listeners

1,320 Listeners

65 Listeners

80 Listeners

30 Listeners

64 Listeners

4 Listeners

58 Listeners

233 Listeners

230 Listeners

69 Listeners

87 Listeners

80 Listeners

81 Listeners

85 Listeners

403 Listeners

19 Listeners

14 Listeners

7 Listeners

2 Listeners

119 Listeners

24 Listeners